Sodium valproate has a prophylactic effect in migraine without aura: A triple-blind, placebo-controlled crossover study

Neurology

Volumn 44, Issue 4, 1994, Pages 647-651

  Jensen, Rigmor ^a   Brinck, Thomas ^a   Olesen, Jes ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DEPRAKINE RETARD; PLACEBO; UNCLASSIFIED DRUG; VALPROIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG USE; DYSPNEA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MALE; MIGRAINE; NECK PAIN; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHOULDER PAIN; SUSTAINED RELEASE PREPARATION;

ADULT; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; MUSCLE CONTRACTION; PLACEBOS; SENSATION DISORDERS; TIME FACTORS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 0028213987     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.44.4.647     Document Type: Article

References (24)

1. Saxena P, Ferrari MD. 5-HT1-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci 1989;10:200-204.
2. Rasmussen BK, Jensen R, Olesen J. Impact of headache on sickness absence and utilization of medical services: a Danish population study. J Epidemiol Community Health 1992;46:443-446.
3. Tfelt-Hansen P, Standnes B, Kangasneimi P, Hakkarainen Olesen J. Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand 1984;69:1-8.
4. Louis P. A double-blind placebo-controlled prophylactic study of flunarizine in migraine. Headache 1981;21:235-239.
5. Sorensen KV. Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand 1988;78:346-348.
6. Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992;12:81-84.
7. International Headache Society on clinical trials in migraine. Guidelines for controlled trials of drugs in migraine. Cephalalgia 1991;11:1-12.
8. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7): 19-28.
9. Olesen J, Krabbe A, Tfelt-Hansen P. Methodological aspects of prophylactic trials in migraine. Cephalalgia 1981;1:127-141.
10. Tfelt-Hansen P, Olesen J. Methodological aspects of drug trials in migraine. Neuroepidemiology 1985;4:204-226.
11. Sorensen PS, Hansen K, Olesen J. A placebo-controlled, double-blind cross-over trial of flunarizine in common migraine. Cephalalgia 1986;6:7-14.
12. Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache: an open-label study. Headache 1991;31:71-74.
13. Gram L, Bentsen KD. Valproate: an updated review. Acta Neurol Scand 1985;72:129-139.
14. Gram L, Flachs H, Wiirtz-Jorgensen A, Parmas J, Andersen B. Valproate, serum levels and clinical effect in epilepsy: a controlled study. Epilepsia 1979;20:303-312.
15. Dreifuss FE, Langer DH. Side effects of valproate. Am J Med 1989;84(suppl 1A):34.
16. Ahmed J, Brown C. In-utero exposure to valproate and neural tube defects. Lancet 1986;1:1392-1393.
17. Tfelt-Hansen P. Efficacy of beta-blockers in migraine: a critical review. Cephalalgia 1986;6(suppl 5): 15-24.
18. Nishikawa T, Scatton B. Inhibitory influence of GABA on central serotonergic transmission: raphe nuclei as the neu- roanatomical site of the GABAergic inhibition of cerebral serotonergic neurons. Brain Res 1985;331:91-103.
19. Goadsby P, Piper RD, Lambert GA, Lance JW. Effect of stimulation of nucleus raphe dorsalis on carotid blood flow. The monkey. Am J Physiol 1985;248:257-267.
20. Welsh KMA, D’Andrea G, Tepley N, Barkly G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin 1989;8(4):817-828.
21. Mac Donald RL. Mechanisms of anticonvulsant drug action. In: Pedley TA, Meldrum BS. Recent advances in epilepsy. I. Edinburgh: Churchill Livingstone, 1983:1-23.
22. Horrobin OF. Prevention of migraine by reducing prolactin levels? Lancet 1973;1:777.
23. Papakostas Y, Daras M, Markianos M, Stefanis C. Increased prolactin response to thyrotropin-releasing hormone during migraine attacks. J Neurol Neurosurg Psychiatry 1987;50:927-928.
24. Racagni G, Apud JA, Cocchi D, Locatelli V, Muller EE. GABAergic control of anterior pituitary hormone secretion. Minireview Life Sci 1982;31:823-838.